Navigation

trimethobenzamide (Tigan)

 

Classes: Antiemetic Agents

Dosing and uses of Tigan (trimethobenzamide)

 

Adult dosage forms and strengths

capsules

  • 300mg

injectable solution

  • 100mg/mL

 

Emesis

300 mg PO q6-8hr Or

200 mg IM q6-8hr

 

Renal Impairment

CrCl<70 mL/min: Consider a lower dose

 

Pediatric dosage forms and strengths

capsules

  • 300mg

 

Emesis

20 mg/kg/day PO divided q6-8hr

 

Geriatric dosage forms and strengths

Consider lower initial dose

 

Emesis

300 mg PO q6-8hr Or

200 mg IM q6-8hr  

 

Tigan (trimethobenzamide) adverse (side) effects

Frequency not defined

Dizziness

Parkinson-like symptoms

Sedation

Headache

Hypersensitivity reactions

Irritation at injection site

 

Warnings

Contraindications

Hypersensitivity to trimethobenzamide

Premature infants or neonates

Injection contraindicated in children

Do not use IV

Children with suspected Reye's syndrome

 

Cautions

Hypotension may occur after deep IM injection

Suppositories discontinued due to lack of effectiveness

 

Pregnancy and lactation

Pregnancy category: C

Lactation: unknown whether drug is distributed into breast milk; avoid

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Tigan (trimethobenzamide)

Mechanism of action

Unclear, the drug appears to directly affect medullary chemoreceptor trigger zone by inhibiting emetic stimuli to the vomiting center

 

Pharmacokinetics

Onset: 15-35 min (IM), 10-40 min (PO)

Duration: 2-3 hr (IM), 3-4 hr (PO)

Bioavailability: BA of oral dose equals 60-100% of IM dose

Half-life elimination: 7-9hr

Metabolism: Liver

Metabolites: N-desmethyl & N-oxide derivatives

Excretion: Urine (30-50%), feces via bile